Eye health company Bausch + Lomb has unveiled its StableVisc cohesive ophthalmic viscosurgical device (OVD) and TotalVisc Viscoelastic System in the US.
The StableVisc OVD and TotalVisc are specified for use as surgical aids in ophthalmic anterior segment procedures like extraction of a cataract, and implantation of an intraocular lens (IOL).
The OVDs also offer eye surgeons new options for dual-action protection during cataract surgery.
StableVisc is said to aid in maintaining room in the anterior chamber of the eye so that doctors can remove and swap out the clouded natural lens.
Bausch + Lomb said that the TotalVisc Viscoelastic System consists of StableVisc and ClearVisc, which is a dispersive OVD that protects ocular tissue in the surgical procedure.
The US Food and Drug Administration (FDA) approved ClearVisc in 2021.
Bausch + Lomb Global Consumer, Surgical and Vision Care president Joe Gordon said: “OVDs are critical to surgeons’ success when performing cataract surgery, which is one of the most common surgical procedures performed in the United States.
“StableVisc and TotalVisc provide surgeons with new OVD options that offer unique benefits designed to help ensure the best possible surgical outcomes for patients.”
Both StableVisc and ClearVisc are composed of sodium hyaluronate and sorbitol, which is a chemical compound that produces a robust physical barrier and offers improved free radical scavenging abilities in comparison to other OVDs examined in a study.
According to the eye health company, TotalVisc OVD delivers dual-action mechanical and chemical protection.
TotalVisc is claimed to be the only dual pack in the US that has a dispersive and cohesive OVD formulated with sorbitol.
StableVisc serves the cohesive OVD sector in fill volume at one millilitre. This lowers the need to open a second pack mid-procedure and improves surgical efficiency. Additionally, StableVisc provides enhanced free radical protection.
TotalVisc is also said to have the highest fill volume in the dual-pack OVD market with one millilitre each of ClearVisc and StableVisc in the device.
